Skip to content

Nuvalent, Inc. NUVL Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$3.14M+124%
Summit Therapeutics logo
Summit TherapeuticsSMMT
$12.22M+658%
Exelixis logo
ExelixisEXEL
$4.04M-12.2%
Revolution Medicines, Inc. logo
Revolution Medicines, Inc.RVMD
-$16.74M-1,181%
Incyte logo
IncyteINCY
-$84.73M-213%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-$7.9M-104%

Other financials

Income statement

See full
Operating income-$119.4M-25.9%
Net income-$109.3M-29.2%
EPS (diluted)-$1.39-17.8%

Balance sheet

See full
Cash & equivalents$159.7M+32.2%
Total equity$1.2B+16.2%
Total assets$1.3B+20.4%

Cash flow

See full
Operating cash flow-$92.4M-68.5%

Valuation

See full
Market cap$9.77B+58.6%

Returns & leverage

See full
Return on equity-41.2%+7.5pp
Current ratio16.1×+1.7×

Where this comes from

Reported directly by Nuvalent, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Nuvalent, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvalent, Inc.'s change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvalent, Inc.'s change in accrued liabilities?
Nuvalent, Inc. (NUVL) reported change in accrued liabilities of -$2.13M in Q1 2026.
How has Nuvalent, Inc.'s change in accrued liabilities changed year-over-year?
Nuvalent, Inc.'s change in accrued liabilities decreased by 471.8% year-over-year, from -$373K to -$2.13M.
What is the long-term trend for Nuvalent, Inc.'s change in accrued liabilities?
Over 3 years (2021 to 2024), Nuvalent, Inc.'s change in accrued liabilities has grown at a 90.9% compound annual growth rate (CAGR), from $3.86M to $26.86M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.